EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Fezolinetant compared with elinzanetant for the treatment of vasomotor symptoms associated with menopause: A matching-adjusted indirect comparison

Petra Stute, Marla Shapiro C M, Antonia Morga, Ting-An Tai, Mayank Ajmera, Bogdan Muresan, Karla Martins, Yechu Hua, Angela Zhao, Jingyi Liu, Rossella E Nappi

Maturitas · 2026

DOI: 10.1016/j.maturitas.2025.108782 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Maturitas, 2026. Verfasst von Petra Stute und 10 weiteren Autor:innen. Beteiligte Einrichtung: University Clinic for Gynecology, Inselspital, Bern, Switzerland. Hauptthemen laut MEDLINE: Menopause, Hot Flashes, Vasomotor System, Heterocyclic Compounds, 4 or More Rings. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Astellas Pharma, Astellas Pharma Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MenopauseHot FlashesVasomotor SystemHeterocyclic Compounds, 4 or More RingsPyrrolidinesHumansFemaleMiddle AgedQuality of LifeTreatment OutcomePatient Reported Outcome MeasuresSurveys and QuestionnairesHeterocyclic Compounds, 2-RingThiadiazoles

Stichwörter der Autor:innen

ElinzanetantFezolinetantMatching-adjusted indirect comparisonNeurokinin 3 receptor antagonistVasomotor symptoms due to menopause

Substanzen

fezolinetantHeterocyclic Compounds, 4 or More RingsPyrrolidinesHeterocyclic Compounds, 2-RingThiadiazoles

Autor:innen und Institutionen

  • University Clinic for Gynecology, Inselspital, Bern, Switzerland.
  • University of Toronto, Toronto, ON, Canada.
  • Astellas Pharma Europe Ltd., Addlestone, Surrey, UK.
  • Astellas Pharma Co., Ltd, Dublin, Ireland.
  • Astellas Pharma Global Development, Inc., Northbrook, IL, USA.
  • Astellas Pharma Europe BV, Leiden, Netherlands.

Förderung

  • Astellas Pharma
  • Astellas Pharma Inc

Zitieren

APA

Stute, P., Shapiro C M, M., Morga, A., Tai, T. A., Ajmera, M., Muresan, B., Martins, K., Hua, Y., Zhao, A., Liu, J., & Nappi, R. E. (2026). Fezolinetant compared with elinzanetant for the treatment of vasomotor symptoms associated with menopause: A matching-adjusted indirect comparison. Maturitas. https://doi.org/10.1016/j.maturitas.2025.108782

Vancouver

Stute P, Shapiro C M M, Morga A, Tai TA, Ajmera M, Muresan B, et al. Fezolinetant compared with elinzanetant for the treatment of vasomotor symptoms associated with menopause: A matching-adjusted indirect comparison. Maturitas. 2026. doi:10.1016/j.maturitas.2025.108782

BibTeX
@article{Stute2026,
  author = {Stute, Petra and Shapiro C M, Marla and Morga, Antonia and Tai, Ting-An and Ajmera, Mayank and Muresan, Bogdan and Martins, Karla and Hua, Yechu and Zhao, Angela and Liu, Jingyi and Nappi, Rossella E},
  title = {Fezolinetant compared with elinzanetant for the treatment of vasomotor symptoms associated with menopause: A matching-adjusted indirect comparison},
  journal = {Maturitas},
  year = {2026},
  doi = {10.1016/j.maturitas.2025.108782}
}
Kostenlos starten →